Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD1473 in Patients with Crohn's Disease

DUBLIN Nov. 20 2018 PRNewswire Theravance Biopharma Inc. NASDAQ TBPH "Theravance Biopharma" or the "Company" today announced dosing of the first patient in a Phase 2 clinical trial of TD1473 in patients with...